Figure 3 : AICAR or rapamycin treatment counteracts muscle wasting in cancer cachexia.

From: Aerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating Autophagy in Colon Cancer

Figure 3

(a) Western blot showing total and phosphorylated AMPK levels, as well as ACC activation (p-ACC) in AICAR-treated mice, and (b) total and phosphorylated mTOR levels in rapamycin-treated mice (RAPA), compared with vehicle-treated mice (—) as well as untreated mice (CTR). Treatments consisted in daily IP injection of vehicle or [250 mg/Kg] AICAR (AICAR) or [2 mg/Kg] rapamycin (RAPA) for 19 days. (c) TA muscle weight of C26-bearing mice in the absence (—) or presence of treatment as indicated. ANOVA (F = 9.47; df 2; p < 0.0005) revealed a significant effect of the treatments on TA weight. (d) Representative immunostaining for laminin on TA muscle of C26-bearing mice in the presence of the treatments indicated, showing increased fiber size in treated animals. Scale bar = 100 microns. (e) Median ± SEM of TA myofiber cross-sectional area of C26-bearing mice in the presence of the treatments indicated. ANOVA (F = 6.86; df 2; p < 0.008) revealed a significant effect of treatments on muscle fiber CSA (F, see results). Data are shown as mean ± SEM; 12 < n < 26 for each group, * p < 0.05 by Tukey’s HSD test.